Product Details
Mar-Ondansetron ODT Tablet
Ondansetron Hydrochloride8 mg
DIN/PIN/NPN
02514974
Manufacturer
Marcan Pharmaceuticals Inc.
Formulary Listing Date
2022-05-31
Unit Price
4.9930
Amount MOH Pays
3.8840
Coverage Status
Limited Use Product
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
A04AA01
Interchangeable Products
| DIN/ PIN/ NPN | Brand name | Unit Price | Amount MOH pays |
|---|---|---|---|
| 02239373 | Zofran ODT (Tablet) | 23.8890 | 3.8840 |
| 02444682 | VPI-Ondansetron ODT (Tablet) | 4.9930 | 3.8840 |
| 02389991 | Ondissolve ODF (Film) | 4.9930 | 3.8840 |
| 02481731 | Ondansetron ODT (Tablet) | 4.9930 | 3.8840 |
| 02487349 | Mint-Ondansetron ODT (Tablet) | 4.9930 | 3.8840 |
| 02511290 | Auro-Ondansetron ODT (Tablet) | 4.9930 | 3.8840 |
| 02514974 | Mar-Ondansetron ODT Tablet | 4.9930 | 3.8840 |
| 02519240 | Ondansetron ODT (Tablet) | 4.9930 | 3.8840 |
| 02519453 | PMS-Ondansetron ODT Tablet | 4.9930 | 3.8840 |
| 02524287 | Ondansetron ODT (Tablet) | 4.9930 | 3.8840 |
| 02535327 | Accel-Ondansetron ODT (Tablet) | 3.8840 | 3.8840 |
| 02541378 | Jamp Ondansetron ODF | 4.9930 | 3.8840 |
LU Clinical Criteria
| LU Code | Auth. Period | Clinical Criteria |
|---|---|---|
| Note: The therapeutic value of Ondansetron Hydrochloride more than 24 hours after the last dose of chemotherapy is unproven | ||
| 215 | 1 year | For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy |
| 216 | 1 year | For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics |
| 217 | 1 year | For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics |
| 218 | 1 year | For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation. |
| 454 | 1 year | For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens |
EAP Criteria
| Therapeutic Class | Reimbursement Criteria |
|---|---|
| Unclassified EAP Drugs | These drugs are not currently listed in the Exceptional Access Program Reimbursement Criteria for Frequently Requested Drugs – August 8, 2023 Edition Physicians may wish to contact the EAP directly by phone at 416-327-8109 or 1-866-811-9893 or by email at EAPFeedback.MOH@ontario.ca to see if an unlisted drug product and/or indication may be considered for EAP funding. |